Sold as Rapivab. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Peramivir (sold as Rapivab), first approved Dec 19, 2014, with 2 new uses approved and 0 published complete response letters.
| Efficacy and Safety of Inhaled Peramivir Solution for the Treatment of Adults With Uncomplicated InfluenzaInfluenza Infection · Capital Medical University | Phase 3 | Not yet recruiting | Aug 27, 2026 |
| A/Texas Flu ChallengeInfluenza · Emory University | Phase 1 | Recruiting | Dec 31, 2024 |
| A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic InfluenzaInfluenza, Influenza, Human · University of Oxford | Phase 2 | Recruiting | Dec 13, 2022 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
